NCT00823862: Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 1 | 34 | Europe | SD-101, CpG Class C Immunostimulatory Sequence (ISS), TLR9 Agonist, ribavirin | Dynavax Technologies Corporation, Synteract, Inc., PPD | Chronic Hepatitis C | 12/09 | 02/10 | | |
